 Connection
Brooke Fridley to Deoxycytidine
This is a "connection" page, showing publications Brooke Fridley has written about Deoxycytidine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.697 |
|
|
|
-
Chalise P, Batzler A, Abo R, Wang L, Fridley BL. Simultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysis. OMICS. 2012 Jul-Aug; 16(7-8):363-73.
Score: 0.417
-
Li L, Zhang JW, Jenkins G, Xie F, Carlson EE, Fridley BL, Bamlet WR, Petersen GM, McWilliams RR, Wang L. Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. Pharmacogenet Genomics. 2016 Dec; 26(12):527-537.
Score: 0.142
-
Li L, Fridley BL, Kalari K, Niu N, Jenkins G, Batzler A, Abo RP, Schaid D, Wang L. Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines. BMC Genomics. 2014 Feb 01; 15:93.
Score: 0.117
-
Brisbin A, Fridley BL. Bayseian genomic models for the incorporation of pathway topology knowledge into association studies. Stat Appl Genet Mol Biol. 2013 Aug; 12(4):505-16.
Score: 0.113
-
Ellsworth KA, Eckloff BW, Li L, Moon I, Fridley BL, Jenkins GD, Carlson E, Brisbin A, Abo R, Bamlet W, Petersen G, Wieben ED, Wang L. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. PLoS One. 2013; 8(8):e70216.
Score: 0.113
-
Breheny P, Chalise P, Batzler A, Wang L, Fridley BL. Genetic association studies of copy-number variation: should assignment of copy number states precede testing? PLoS One. 2012; 7(4):e34262.
Score: 0.103
-
Fridley BL, Lund S, Jenkins GD, Wang L. A Bayesian integrative genomic model for pathway analysis of complex traits. Genet Epidemiol. 2012 May; 36(4):352-9.
Score: 0.103
-
Li L, Schaid DJ, Fridley BL, Kalari KR, Jenkins GD, Abo RP, Batzler A, Moon I, Pelleymounter L, Eckloff BW, Wieben ED, Sun Z, Yang P, Wang L. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet Genomics. 2012 Feb; 22(2):105-16.
Score: 0.102
-
Fridley BL, Batzler A, Li L, Li F, Matimba A, Jenkins GD, Ji Y, Wang L, Weinshilboum RM. Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics. 2011 Nov; 21(11):701-12.
Score: 0.100
-
Fridley BL, Jenkins GD. Localizing putative markers in genetic association studies by incorporating linkage disequilibrium into bayesian hierarchical models. Hum Hered. 2010; 70(1):63-73.
Score: 0.091
-
Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, Wang L. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One. 2009 Nov 09; 4(11):e7765.
Score: 0.087
-
Fridley BL, Jenkins G, Schaid DJ, Wang L. A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity. Stat Med. 2009 Sep 20; 28(21):2709-22.
Score: 0.086
-
Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D, Wang L. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res. 2008 Sep 01; 68(17):7050-8.
Score: 0.080
-
Oesterheld JE, Reed DR, Setty BA, Isakoff MS, Thompson P, Yin H, Hayashi M, Loeb DM, Smith T, Makanji R, Fridley BL, Wagner LM. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. Pediatr Blood Cancer. 2020 07; 67(7):e28370.
Score: 0.045
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|